ReBio
2 known investors
ReBio develops targeted, locally delivered therapies for ocular oncology, using its proprietary SiSu conjugate platform to program drug exposure for eye diseases. Its lead program, RBP-01, is a SiSu-conjugated PKC inhibitor for uveal melanoma delivered via intravitreal injection, with additional programs targeting retinoblastoma, glaucoma, and post-op ocular inflammation.
Founders & leadership
RR
Roi RazinCEOPreviously chief financial officer at Trigone Pharma and senior director of investor relations at Moderna, following work as a pharma and biotech equity analyst at AtonRâ Partners. He earlier managed biotech portfolios at Adamas Capital Management/Mascall Management and spent six years at Barak Capital as an investment analyst and portfolio manager.
Investors · 2
Frequently asked questions
- What does ReBio do?
- ReBio develops targeted, locally delivered therapies for ocular oncology, using its proprietary SiSu conjugate platform to program drug exposure for eye diseases. Its lead program, RBP-01, is a SiSu-conjugated PKC inhibitor for uveal melanoma delivered via intravitreal injection, with additional programs targeting retinoblastoma, glaucoma, and post-op ocular inflammation.
- Who are ReBio's investors?
- ReBio's investors include Kinled Holding, SICTIC.